Athenex 
Welcome,         Profile    Billing    Logout  
 12 Products   23 Diseases  12 Products   15 Trials   606 News 
34 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oraxol (oral paclitaxel/encequidar) / Hope Pharm
HHP-ORAX-300, NCT06835400: Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Not yet recruiting
3
340
NA
Paclitaxel Capsule, IV Paclitaxel, Encequidar tablet
Health Hope Pharma
Metastatic Breast Cancer
04/28
05/29
2017-004578-33: A Safety Study of Oraxol in Cancer Patients

Not yet recruiting
2
40
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, paclitaxel tablets, Tablet, Capsule, hard
Athenex, Inc., Athenex, Inc
Cancer patients for whom treatment with IV paclitaxel at 80 mg/m2 has been recommended by their oncologist, either as monotherapy or in combination with other agents, Cancer, Diseases [C] - Cancer [C04]
 
 
2019-002085-13: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma

Not yet recruiting
2
43
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, Tablet, Capsule, hard
Athenex, Inc, Athenex, Inc
Study of Oraxol in Subjects with Cutaneous Angiosarcoma, Soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
KX-ORAX-010 , NCT03544567 / 2019-002085-13: A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Completed
2
48
Europe, US, RoW
Oraxol, oral HM30181A + oral paclitaxel
Athenex, Inc., Athenex, Inc
Angiosarcoma of Skin
05/23
05/23
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02970539: Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Active, not recruiting
1b
36
US, RoW
Oraxol, oral HM30181AK-US tablet and paclitaxel capsule, Ramucirumab, LY3009806
Athenex, Inc.
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
03/19
12/22
ACTRN12614000365662: An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1

Recruiting
1
8
 
Kinex Pharmaceuticals, Inc., Kinex Pharmaceuticals, Inc.
Cancer
 
 
ChiCTR1900021427: A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Not yet recruiting
1
24
 
Drug therapy
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, sponsor
Breast Cancer
 
 
KEYNOTE-E06, NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Checkmark Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Sep 2021 - Sep 2021: Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Terminated
1
34
US
Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda
Athenex, Inc., Merck Sharp & Dohme LLC
Solid Tumor
05/23
05/23
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
1
29
Europe
Oraxol, Paclitaxel and HM30181AK-US
Athenex, Inc.
Solid Tumor, Adult
05/23
05/23
tirbanibulin oral (KX-01 oral) / Athenex
2021-004349-18: Long-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. Estudio de seguridad clínica a largo plazo para evaluar el riesgo de que la queratosis actínica (QA) progrese a cáncer de piel tras el tratamiento en cara o cuero cabelludo con tirbanibulina 10 mg/g pomada comparado con diclofenaco 3% gel en pacientes adultos. La tirbanibulina y el diclofenaco se usan para tratar adultos con QA en cara y cuero cabelludo. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar

Not yet recruiting
4
540
Europe
Solaraze 3% gel, Klisyri 10 mg/g unguento, [NA], Ointment, Gel, Klisyri 10 mg/g ointment, Solaraze 3%, gel
Almirall, S.A., Almirall SA, Almirall, S.A.
Actinic Keratosis on the Face or Scalp Queratosis actínica en la cara o el cuero cabelludo, Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2022-001251-16: Open phase IV study to assess the impact of tirbanibulin on the well-being of patients with actinic keratoses (TIRBASKIN). Estudio abierto de fase IV para evaluar el impacto de tirbanibulina en el bienestar de los pacientes con queratosis actínica (TIRBASKIN).

Ongoing
4
420
Europe
Tirbanibulin, M-14789-42, Ointment, Klisyri
Almirall, S.A., Almirall S.A.
Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
Tir2401, NCT06648447: Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses with Downward-directed Proliferation Patterns

Not yet recruiting
N/A
20
NA
Thomas Dirschka
Actinic Keratosis (AK)
02/25
03/25
TAEST16001 / Guangzhou Xiangxue Pharma, Athenex
NCT05549921: Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Recruiting
2
70
RoW
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
09/24
09/24
ChiCTR-OIC-17013872: To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in bone and soft tissue sarcoma

Not yet recruiting
1
20
 
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Xiangxue Life Science Research Center Guangdong Xiangxue Precision Medical Technology Co., Ltd Guangzhou Xiangxue Pharmaceutical Co., Ltd
bone and soft tissue sarcoma
 
 
CTR20192611: Phase I clinical study of TAEST16001 injection in patients with solid tumors

Completed
1
18
China
TAEST16001 - Guangzhou Xiangxue Pharma, Athenex
Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Advanced malignant solid tumors, mainly soft tissue sarcomas
 
 
NCT04318964: TAEST16001 in the Treatment of Soft Tissue Sarcoma

Active, not recruiting
1
12
RoW
TAEST16001 cells
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
04/22
05/24
NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Active, not recruiting
1
20
RoW
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Bone Sarcoma, Soft Tissue Sarcoma
02/24
05/24
ChiCTR2000031226: An open, single arm and early clinical study of TAEST16001 in the treatment of solid tumor mainly containing soft tissue sarcoma with positive expression of tumor antigen NY-ESO-1 (HLA-A * 02:01)

Recruiting
N/A
12
 
TAEST16001 cells treat tumor antigen NY-ESO-1
Sun Yat-Sen University Cancer center; Sun Yat-Sen University Cancer Center, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
soft tissue sarcoma
 
 
KUR-501 / Athenex
GINAKIT2, NCT03294954: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma

Recruiting
1
54
US
GINAKIT Cells, GINAKIT cells + Etanercept
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine
Neuroblastoma
07/25
08/40
pegtomarginase (PT-01) / Athenex
PT01, NCT04136834: A Phase I Open-label Study for Subjects With Advanced Malignancies

Recruiting
1
62
US
PT01 (Pegtomarginase)
Athenex, Inc.
Advanced Solid Malignancies
12/22
12/22
Klisyri (tirbanibulin ointment) / Hanmi, Almirall, Athenex, PharmaEssentia
2022-003326-44: SunDamage: Tirbanibulin salve for the treatment of chronically sun-damaged skin on the face

Ongoing
4
20
Europe
Klisyri, Ointment, Klisyri® (Tirbanibulin)
Medizinische Universität Graz, Universitätsklinik für Dermatologie und Venerologie, Almirall GmbH
Subclinical lesions in UV-exposed areas of chronically UV-damaged skin in the face adjacent to lesions caused by actinic keratosis but not obviously affected themselves., Facial skin areas chronically damaged by sunlight (UV light), Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
TIRBASKIN, NCT05741294 / 2022-001251-16: A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Completed
4
334
Europe
Tirbanibulin 2.5 mg ointment
Almirall, S.A., Almirall S.A.
Actinic Keratosis
01/24
01/24
SunDamage, NCT05900258: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

Completed
4
22
Europe
Tirbanibulin
Medical University of Graz
Actinic Keratosis
11/23
11/23
NCT06026358: Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

Withdrawn
4
30
NA
Tirbanibulin
Medical University of Graz, Almirall, SAS
Actinic Keratoses
12/24
12/24
NCT06791525: Tirbanibulin for Pediatric Warts

Recruiting
4
10
US
Tirbanibulin ointment 1%
The Skin Center Dermatology Group
Warts Hand
11/25
12/25
NCT05387525 / 2021-004349-18: A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

Active, not recruiting
4
447
Europe
Tirbanibulin (Klisyri®) 10 mg/g ointment, Klisyri®, Diclofenac Sodium 3% Gel
Almirall, S.A., Almirall, S.A.
Keratosis, Actinic
07/27
07/27
NCT05231044: A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Completed
3
108
Japan
KX01 ointment 1%, Placebo
PharmaEssentia, PharmaEssentia Japan K.K.
Actinic Keratosis
11/23
11/23
TirbAKare, NCT06135415: A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Active, not recruiting
3
280
Europe
Tirbanibulin, Klisyri®, Vehicle ointment
Almirall, S.A.
Keratosis, Actinic
04/26
11/26
NCT05713760: Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Completed
2
5
US
Tirbanibulin Ointment 1%, Klisyri (tirbanibulin ointment 1%)
Austin Institute for Clinical Research
Superficial Basal Cell Carcinoma
03/24
03/24
NCT07010692: Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Recruiting
1/2
100
US
Tirbanibulin ointment 1%, non-ablative fractional laser
Bruce Robinson, MD
Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
05/30
06/30
PROAK, NCT05260073: Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

Completed
N/A
300
US
Tirbanibulin, Klisyri®
Almirall, S.A.
Keratosis, Actinic
10/22
03/23
KUR-502 / Athenex
ANCHOR2, NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Recruiting
1
36
US
KUR-502, CD19.CAR-aNKT cells
Athenex, Inc.
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
12/23
12/24
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies

Active, not recruiting
1
13
US
CD19.CAR-aNKT cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
06/26
02/35
p53/KRAS/EGFR targeted NK cell therapy / Athenex
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oraxol (oral paclitaxel/encequidar) / Hope Pharm
HHP-ORAX-300, NCT06835400: Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Not yet recruiting
3
340
NA
Paclitaxel Capsule, IV Paclitaxel, Encequidar tablet
Health Hope Pharma
Metastatic Breast Cancer
04/28
05/29
2017-004578-33: A Safety Study of Oraxol in Cancer Patients

Not yet recruiting
2
40
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, paclitaxel tablets, Tablet, Capsule, hard
Athenex, Inc., Athenex, Inc
Cancer patients for whom treatment with IV paclitaxel at 80 mg/m2 has been recommended by their oncologist, either as monotherapy or in combination with other agents, Cancer, Diseases [C] - Cancer [C04]
 
 
2019-002085-13: A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma

Not yet recruiting
2
43
Europe
Oraxol, HM30181AK-US, paclitaxel capsules, Tablet, Capsule, hard
Athenex, Inc, Athenex, Inc
Study of Oraxol in Subjects with Cutaneous Angiosarcoma, Soft tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
KX-ORAX-010 , NCT03544567 / 2019-002085-13: A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Completed
2
48
Europe, US, RoW
Oraxol, oral HM30181A + oral paclitaxel
Athenex, Inc., Athenex, Inc
Angiosarcoma of Skin
05/23
05/23
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT02970539: Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

Active, not recruiting
1b
36
US, RoW
Oraxol, oral HM30181AK-US tablet and paclitaxel capsule, Ramucirumab, LY3009806
Athenex, Inc.
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
03/19
12/22
ACTRN12614000365662: An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1

Recruiting
1
8
 
Kinex Pharmaceuticals, Inc., Kinex Pharmaceuticals, Inc.
Cancer
 
 
ChiCTR1900021427: A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Not yet recruiting
1
24
 
Drug therapy
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, sponsor
Breast Cancer
 
 
KEYNOTE-E06, NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Checkmark Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Sep 2021 - Sep 2021: Interim data in combination with Paclitaxel for NSCLC and advance solid tumor at ESMO
Terminated
1
34
US
Oraxol, oral HM30181A + oral paclitaxel, Pembrolizumab, Keytruda
Athenex, Inc., Merck Sharp & Dohme LLC
Solid Tumor
05/23
05/23
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
1
29
Europe
Oraxol, Paclitaxel and HM30181AK-US
Athenex, Inc.
Solid Tumor, Adult
05/23
05/23
tirbanibulin oral (KX-01 oral) / Athenex
2021-004349-18: Long-term clinical safety study to evaluate the risk of actinic keratosis progressing to skin cancer following treatment of the face or scalp with tirbanibulin 10 mg/g ointment and in comparison to diclofenac 3% gel in adult patients. Tirbanibulin and diclofenac are used to treat adults with actinic keratosis on the face and scalp. Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. Estudio de seguridad clínica a largo plazo para evaluar el riesgo de que la queratosis actínica (QA) progrese a cáncer de piel tras el tratamiento en cara o cuero cabelludo con tirbanibulina 10 mg/g pomada comparado con diclofenaco 3% gel en pacientes adultos. La tirbanibulina y el diclofenaco se usan para tratar adultos con QA en cara y cuero cabelludo. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar

Not yet recruiting
4
540
Europe
Solaraze 3% gel, Klisyri 10 mg/g unguento, [NA], Ointment, Gel, Klisyri 10 mg/g ointment, Solaraze 3%, gel
Almirall, S.A., Almirall SA, Almirall, S.A.
Actinic Keratosis on the Face or Scalp Queratosis actínica en la cara o el cuero cabelludo, Actinic keratosis is a precancerous, abnormal skin growth that develops after too much exposure to sunlight. La queratosis actínica es un crecimiento anormal y precanceroso de la piel que se desarrolla después de una exposición excesiva a la luz solar., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
2022-001251-16: Open phase IV study to assess the impact of tirbanibulin on the well-being of patients with actinic keratoses (TIRBASKIN). Estudio abierto de fase IV para evaluar el impacto de tirbanibulina en el bienestar de los pacientes con queratosis actínica (TIRBASKIN).

Ongoing
4
420
Europe
Tirbanibulin, M-14789-42, Ointment, Klisyri
Almirall, S.A., Almirall S.A.
Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Tirbanibulin is a new topical treatment for actinic keratosis (AK) of the face and scalp. La tirbanibulina es un nuevo tratamiento tópico para la queratosis actínica (QA) de la cara y el cuero cabelludo., Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
Tir2401, NCT06648447: Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses with Downward-directed Proliferation Patterns

Not yet recruiting
N/A
20
NA
Thomas Dirschka
Actinic Keratosis (AK)
02/25
03/25
TAEST16001 / Guangzhou Xiangxue Pharma, Athenex
NCT05549921: Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Recruiting
2
70
RoW
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
09/24
09/24
ChiCTR-OIC-17013872: To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in bone and soft tissue sarcoma

Not yet recruiting
1
20
 
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Xiangxue Life Science Research Center Guangdong Xiangxue Precision Medical Technology Co., Ltd Guangzhou Xiangxue Pharmaceutical Co., Ltd
bone and soft tissue sarcoma
 
 
CTR20192611: Phase I clinical study of TAEST16001 injection in patients with solid tumors

Completed
1
18
China
TAEST16001 - Guangzhou Xiangxue Pharma, Athenex
Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Advanced malignant solid tumors, mainly soft tissue sarcomas
 
 
NCT04318964: TAEST16001 in the Treatment of Soft Tissue Sarcoma

Active, not recruiting
1
12
RoW
TAEST16001 cells
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
04/22
05/24
NCT03462316: NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma

Active, not recruiting
1
20
RoW
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Bone Sarcoma, Soft Tissue Sarcoma
02/24
05/24
ChiCTR2000031226: An open, single arm and early clinical study of TAEST16001 in the treatment of solid tumor mainly containing soft tissue sarcoma with positive expression of tumor antigen NY-ESO-1 (HLA-A * 02:01)

Recruiting
N/A
12
 
TAEST16001 cells treat tumor antigen NY-ESO-1
Sun Yat-Sen University Cancer center; Sun Yat-Sen University Cancer Center, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
soft tissue sarcoma
 
 
KUR-501 / Athenex
GINAKIT2, NCT03294954: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma

Recruiting
1
54
US
GINAKIT Cells, GINAKIT cells + Etanercept
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine
Neuroblastoma
07/25
08/40
pegtomarginase (PT-01) / Athenex
PT01, NCT04136834: A Phase I Open-label Study for Subjects With Advanced Malignancies

Recruiting
1
62
US
PT01 (Pegtomarginase)
Athenex, Inc.
Advanced Solid Malignancies
12/22
12/22
Klisyri (tirbanibulin ointment) / Hanmi, Almirall, Athenex, PharmaEssentia
2022-003326-44: SunDamage: Tirbanibulin salve for the treatment of chronically sun-damaged skin on the face

Ongoing
4
20
Europe
Klisyri, Ointment, Klisyri® (Tirbanibulin)
Medizinische Universität Graz, Universitätsklinik für Dermatologie und Venerologie, Almirall GmbH
Subclinical lesions in UV-exposed areas of chronically UV-damaged skin in the face adjacent to lesions caused by actinic keratosis but not obviously affected themselves., Facial skin areas chronically damaged by sunlight (UV light), Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
TIRBASKIN, NCT05741294 / 2022-001251-16: A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses

Completed
4
334
Europe
Tirbanibulin 2.5 mg ointment
Almirall, S.A., Almirall S.A.
Actinic Keratosis
01/24
01/24
SunDamage, NCT05900258: Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face

Completed
4
22
Europe
Tirbanibulin
Medical University of Graz
Actinic Keratosis
11/23
11/23
NCT06026358: Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands

Withdrawn
4
30
NA
Tirbanibulin
Medical University of Graz, Almirall, SAS
Actinic Keratoses
12/24
12/24
NCT06791525: Tirbanibulin for Pediatric Warts

Recruiting
4
10
US
Tirbanibulin ointment 1%
The Skin Center Dermatology Group
Warts Hand
11/25
12/25
NCT05387525 / 2021-004349-18: A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp

Active, not recruiting
4
447
Europe
Tirbanibulin (Klisyri®) 10 mg/g ointment, Klisyri®, Diclofenac Sodium 3% Gel
Almirall, S.A., Almirall, S.A.
Keratosis, Actinic
07/27
07/27
NCT05231044: A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Completed
3
108
Japan
KX01 ointment 1%, Placebo
PharmaEssentia, PharmaEssentia Japan K.K.
Actinic Keratosis
11/23
11/23
TirbAKare, NCT06135415: A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis

Active, not recruiting
3
280
Europe
Tirbanibulin, Klisyri®, Vehicle ointment
Almirall, S.A.
Keratosis, Actinic
04/26
11/26
NCT05713760: Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults

Completed
2
5
US
Tirbanibulin Ointment 1%, Klisyri (tirbanibulin ointment 1%)
Austin Institute for Clinical Research
Superficial Basal Cell Carcinoma
03/24
03/24
NCT07010692: Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Recruiting
1/2
100
US
Tirbanibulin ointment 1%, non-ablative fractional laser
Bruce Robinson, MD
Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
05/30
06/30
PROAK, NCT05260073: Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

Completed
N/A
300
US
Tirbanibulin, Klisyri®
Almirall, S.A.
Keratosis, Actinic
10/22
03/23
KUR-502 / Athenex
ANCHOR2, NCT05487651: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

Recruiting
1
36
US
KUR-502, CD19.CAR-aNKT cells
Athenex, Inc.
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
12/23
12/24
ANCHOR, NCT03774654: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies

Active, not recruiting
1
13
US
CD19.CAR-aNKT cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute, National Cancer Institute (NCI)
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
06/26
02/35
p53/KRAS/EGFR targeted NK cell therapy / Athenex
No trials found

Download Options